Status:
COMPLETED
Lanadelumab for Treatment of COVID-19 Disease
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Takeda
Conditions:
COVID-19
Eligibility:
All Genders
16+ years
Phase:
PHASE1
PHASE2
Brief Summary
So far little is very few drugs have demonstrated positive results for treatment of COVID19. Recently the researchers have shown that the use of icatibant in COVID-19 results in a potent decrease in ...
Eligibility Criteria
Inclusion
- Patient is SARS-COV2 positive (PCR)
- Without oxygen a saturation below 90%
- At least 3L/min oxygen dependent
- Patient is 16 years and older
Exclusion
- Has previously participated in this study
- Acute myocardial or cerebral ischemic event at time of enrolment
- Receiving ACE or ARB inhibitor or comparable drugs that is specified as an intervention in this domain as a usual medication prior to this hospitalization will exclude a patient from receiving that agent
- A baseline alanine aminotransferase or an aspartate aminotransferase that is more than five times the upper limit of normal
- Patient is known hypersensitive to full human monoclonal antibodies
- Patient is pregnant or breast feeding
Key Trial Info
Start Date :
October 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04422509
Start Date
October 30 2020
End Date
April 30 2021
Last Update
July 13 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Amsterdam UMC
Amsterdam, Netherlands
2
Rijnstate hospital
Arnhem, Netherlands
3
Radboudumc
Nijmegen, Netherlands
4
UMC Utrecht
Utrecht, Netherlands